ArticleBMJ digital health & AI2025
MedMobile: a mobile-sized language model with clinical capabilities.
Article in BMJ digital health & AI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluating the Performance and Fragility of Large Language Models on the Self-Assessment for Neurological Surgeons.Neurosurgery · 2026Article
- General-purpose large language models outperform specialized clinical AI tools on medical benchmarks.Nature medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Objective: Language models (LMs) have demonstrated expert-level reasoning and recall abilities in medicine. However, computational costs and privacy concerns are mounting barriers to wide-scale implementation. To address these significant limitations, we introduce a parsimonious adaptation of phi-3-mini, MedMobile, a 3.8 billion parameter LM capable of running on a mobile device, for medical applications. Methods and analysis: We perform a careful set of pipeline additions and demonstrate that chain of thought, ensembling and fine-tuning lead to the greatest performance gains, while unexpectedly retrieval augmented generation fails to demonstrate significant improvements. We evaluate the efficiency of our pipeline on the MultiMedQA and Medbullets. Results: We demonstrate that MedMobile scores 75.7% on the MedQA (United States Medical Licensing Examination-like), surpassing the passing mark for licensed physicians (~60%) and rivalling scores of models 100 times its size. Across the entirety of the MultiMedQA, MedMobile achieves state-of-the-art performance for models with less than 5B parameters and represents the smallest model to pass the MedQA. Conclusions: MedMobile holds promise to democratise access to LMs in medicine, bolstering lower compute needs and fast inference speeds. With the ability to combat the biggest barriers to entry for LMs in medicine, we hope that MedMobile is a critical step forward in developing clinically relevant LMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.